LIOTHYRONINE SODIUM Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Liothyronine Sodium, and when can generic versions of Liothyronine Sodium launch?
Liothyronine Sodium is a drug marketed by Xgen Pharms, Biocon Pharma, Dr Reddys Labs Sa, Mylan, Sigmapharm Labs Llc, Sun Pharm, Teva Pharms Usa, Watson Labs, and Zydus. and is included in ten NDAs.
The generic ingredient in LIOTHYRONINE SODIUM is liothyronine sodium. There are four drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the liothyronine sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Liothyronine Sodium
A generic version of LIOTHYRONINE SODIUM was approved as liothyronine sodium by XGEN PHARMS on August 17th, 2005.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LIOTHYRONINE SODIUM?
- What are the global sales for LIOTHYRONINE SODIUM?
- What is Average Wholesale Price for LIOTHYRONINE SODIUM?
Summary for LIOTHYRONINE SODIUM
US Patents: | 0 |
Applicants: | 9 |
NDAs: | 10 |
Finished Product Suppliers / Packagers: | 18 |
Raw Ingredient (Bulk) Api Vendors: | 76 |
Clinical Trials: | 15 |
Patent Applications: | 1,189 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in LIOTHYRONINE SODIUM? | LIOTHYRONINE SODIUM excipients list |
DailyMed Link: | LIOTHYRONINE SODIUM at DailyMed |
Recent Clinical Trials for LIOTHYRONINE SODIUM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Minnesota - Clinical and Translational Science Institute | Phase 1/Phase 2 |
University of Minnesota | Phase 1/Phase 2 |
Aultman Health Foundation | Phase 2 |
Pharmacology for LIOTHYRONINE SODIUM
Drug Class | l-Triiodothyronine |